CA2286137A1 - Facteur de croissance du tissu nerveux pour la prevention de la demyelinisation dans le systeme nerveux - Google Patents

Facteur de croissance du tissu nerveux pour la prevention de la demyelinisation dans le systeme nerveux Download PDF

Info

Publication number
CA2286137A1
CA2286137A1 CA002286137A CA2286137A CA2286137A1 CA 2286137 A1 CA2286137 A1 CA 2286137A1 CA 002286137 A CA002286137 A CA 002286137A CA 2286137 A CA2286137 A CA 2286137A CA 2286137 A1 CA2286137 A1 CA 2286137A1
Authority
CA
Canada
Prior art keywords
ngf
demyelination
nerve
human
protease inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002286137A
Other languages
English (en)
Inventor
Ilse Bartke
Jurgen Unger
Claude Genain
Stephen Hauser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2286137A1 publication Critical patent/CA2286137A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors

Abstract

La présente invention a pour objet un procédé pour la prévention de la démyélinisation des fibres nerveuses, en particulier, des fibres nerveuses de l'homme. Selon ce procédé, les patients sont traités par le facteur de croissance du tissu nerveux, ou par des fragments de ce facteur. En outre, l'invention traite d'une composition pour traiter les maladies impliquant une démyélinisation des fibres nerveuses. Cette composition contient un facteur de croissance du tissu nerveux ou un fragment actif de ce dernier comme substance active, avec les excipients pharmaceutiques classiques, les substances auxiliaires, les charges et les diluants.
CA002286137A 1997-04-11 1998-04-08 Facteur de croissance du tissu nerveux pour la prevention de la demyelinisation dans le systeme nerveux Abandoned CA2286137A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83395997A 1997-04-11 1997-04-11
US08/833,959 1997-04-11
PCT/EP1998/002029 WO1998046254A1 (fr) 1997-04-11 1998-04-08 Facteur de croissance du tissu nerveux pour la prevention de la demyelinisation dans le systeme nerveux

Publications (1)

Publication Number Publication Date
CA2286137A1 true CA2286137A1 (fr) 1998-10-22

Family

ID=25265743

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002286137A Abandoned CA2286137A1 (fr) 1997-04-11 1998-04-08 Facteur de croissance du tissu nerveux pour la prevention de la demyelinisation dans le systeme nerveux

Country Status (3)

Country Link
AU (1) AU7214998A (fr)
CA (1) CA2286137A1 (fr)
WO (1) WO1998046254A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7282482B2 (en) * 1998-04-08 2007-10-16 The Regents Of The University Of California NGF for the prevention of demyelination in the nervous system
CN1112215C (zh) * 1999-12-28 2003-06-25 潘晓东 神经生长因子在治疗有机溶剂中毒性周围神经病中的用途
SE9904863D0 (sv) * 1999-12-30 1999-12-30 Medscand Medical Ab New use
US8066997B2 (en) 2002-12-20 2011-11-29 Anders Nykjaer Modulation of activity of neurotrophins
DE10317369A1 (de) * 2003-04-15 2004-11-11 Scil Proteins Gmbh proNGF als pharmazeutisch wirksames Mittel zur Behandlung demyelinisierender Erkrankungen
HUE048781T2 (hu) 2006-12-21 2020-08-28 H Lundbeck As Proneurotrofinok aktivitásának modulációja

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4125933A1 (de) * 1991-08-05 1993-02-11 Max Planck Gesellschaft Verbesserung der regeneration von oligodendrocyten
EP0731108A1 (fr) * 1995-03-10 1996-09-11 Boehringer Mannheim Gmbh Procédé de fabrication d'un agent thérapeutique pour la régénération d'oligodendrocytes
PT862452E (pt) * 1995-11-07 2004-04-30 Genentech Inc Formulacao de estabilizacao para o ngf

Also Published As

Publication number Publication date
AU7214998A (en) 1998-11-11
WO1998046254A1 (fr) 1998-10-22

Similar Documents

Publication Publication Date Title
US7282482B2 (en) NGF for the prevention of demyelination in the nervous system
Nishida et al. Fibronectin enhancement of corneal epithelial wound healing of rabbits in vivo
Mansour-Robaey et al. Effects of ocular injury and administration of brain-derived neurotrophic factor on survival and regrowth of axotomized retinal ganglion cells.
Sinson et al. Nerve growth factor administration attenuates cognitive but not neurobehavioral motor dysfunction or hippocampal cell loss following fluid‐percussion brain injury in rats
McLean et al. Recurrent erosion: treatment by anterior stromal puncture
Kawamoto et al. Nerve growth factor and wound healing
US5958411A (en) Methods of inhibiting ECM accumulation in the CNS by inhibition of TGF-β
RU2266129C2 (ru) Способ воздействия на нейродегенеративное нарушение или нарушение миелинизации
US6063757A (en) Wound treatment method with nerve growth factor
WO1999032516A2 (fr) Compositions pharmaceutiques contenant une pentraxine longue ptx3
AU641166B2 (en) Treatment to reduce edema for brain and musculature injuries
CA2286137A1 (fr) Facteur de croissance du tissu nerveux pour la prevention de la demyelinisation dans le systeme nerveux
US5510329A (en) Preparations for the treatment of eyes
WO1999003493A1 (fr) Medicaments contenant midkine en tant principe actif ou inhibiteurs desdits medicaments
WO1993008819A1 (fr) Traitement des troubles neurologiques par un compose inhibiteur de l'interleukine-1
AU2002300173B2 (en) NGF for the Prevention of Demyelination in the Nervous System
US20040121958A1 (en) Methods of alleviating neuropathic pain
IL135799A (en) Immunological compositions to transiently alter mammalian central nervous system myelin to promote neuronal regeneration
JP2004500437A (ja) 可動化活性を有する調製物
DE4413938A1 (de) Peptide als Therapeutikum für Autoimmunerkrankungen
Chan et al. Pharmacokinetic study of recombinant human epidermal growth factor in the anterior eye.
Yin et al. Expression of Schwann cell-specific proteins and low-molecular-weight neurofilament protein during regeneration of sciatic nerve treated with neurotrophin-4
EP0878200B1 (fr) Agent therapeutique pour maladies ophtalmiques
Hamdi The effect of topical parasympathomimetics on corneal epithelial healing in rabbits
Rauch et al. Induction and suppression of experimental allergic encephalomyelitis in the non-human primate

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued